AIMS BioScience
AIMS BioScience is a Seoul-based private drug development consulting firm that provides integrated preclinical, clinical pharmacology, pharmacometrics, regulatory, and CRO outsourcing services to biotech, pharma, and research hospital clients, and is Korea's sole provider of quantitative pharmacology services following its 2023 merger with Q-fitter.
- Company typePrivate
- Founded-
- HeadquartersSeoul, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingServices
What AIMS BioScience does
AIMS BioScience Co., Ltd. (주식회사 애임스바이오사이언스) is a Seoul-headquartered, private B2B professional services firm that provides integrated drug development consulting to biopharmaceutical companies and research hospitals. Its core service pillars are Strategy Consulting (Target Product Profile definition, nonclinical/clinical development strategy, study design, regulatory strategy, out-licensing support), Study Outsourcing (management of preclinical, clinical, and translational studies through a network of trusted CRO partners including Charles River, WuXi AppTec, Parexel, and Lovelace Biomedical), and Modeling & Simulation (pharmacometrics including PBPK modeling, PK-PD modeling and simulation, and noncompartmental analysis). The company also holds exclusive Korean distribution rights for EuroscreenFast's GPCR functional assay platform.
The platform is organized as a federation of specialized expert teams — Clinical Pharmacology, Non-clinical, Product Quality/CMC, Pharmacometrics, Clinical Development, Regulatory Strategy, Study Outsourcing, AI Support, and Clinical Research — delivering services across the entire preclinical-to-regulatory-submission continuum. Following its April 2023 merger with Q-fitter, AIMS became the sole provider of quantitative pharmacology services in Korea. The company reports 170+ clients across 320+ completed projects and operates a US branch office in Rockville, Maryland to support cross-border engagements.
AIMS generates revenue through quote-based professional services engagements tailored to project scope and development stage, with no publicly disclosed pricing. The company is privately held with no disclosed venture funding, parent company, or institutional investors. Its competitive positioning rests on multidisciplinary expertise, Korean academic affiliations (notably The Catholic University of Korea and PIPET), and integrated translational methodology rather than on proprietary software or patented technology.
AIMS BioScience firmographics
Firmographics- Name
- AIMS BioScience
- Legal name
- AIMS BioScience Co., Ltd.
- Website
- https://aimsbiosci.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AIMS BioScience is a Seoul-based private drug development consulting firm that provides integrated preclinical, clinical pharmacology, pharmacometrics, regulatory, and CRO outsourcing services to biotech, pharma, and research hospital clients, and is Korea's sole provider of quantitative pharmacology services following its 2023 merger with Q-fitter.
- Ownership category
- akta.pro rank
AIMS BioScience industry classification
Industry- Product category
- Drug Development Consulting Services
- NAICS
- Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Medical Affairs Scientific Communications (MSL Support/Scientific Response) (HLAGALAF)
- akta.pro secondary industries
- Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC)
Keywords
Where AIMS BioScience is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices3 records
Markets served
AIMS BioScience business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
Revenue model
- Strategy Consulting: Comprehensive consulting services for drug development including Target Product Profile definition, nonclinical & clinical development strategy, study design, regulatory strategy, and scientific support for licensing-out
- Study Outsourcing: Management and coordination of drug development studies across preclinical, clinical, and translational phases through a network of trusted CRO partners
- EuroscreenFast Distribution: Official Korean distributor for EuroscreenFast GPCR assays and functional screening services, offering over 1,000 diverse functional assays including GPCR, ion channels, kinases, and enzymes
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
AIMS BioScience product offering
Product offeringCore offering
AIMS BioScience is a Korea-based B2B drug development consulting firm that delivers strategy consulting, study outsourcing, and pharmacometric modeling & simulation services to biotech and pharmaceutical companies. The firm supports clients across preclinical, clinical pharmacology, CMC, regulatory strategy, and licensing-out stages, and is also the official Korean distributor of EuroscreenFast GPCR functional assays.
Product overview
AIMS BioScience is a drug development consulting company offering a comprehensive suite of services across the entire pharmaceutical development lifecycle. The company operates as a single integrated platform rather than a modular architecture, providing strategy consulting, study outsourcing, and modeling & simulation (M&S) as core service pillars. Their portfolio includes distributed products like EuroscreenFast (GPCR assay platform), combined with in-house services spanning pharmacometrics, IND enabling, DMPK, toxicology, CMC consulting, and clinical development. Following the April 2023 merger with Q-fitter (a quantitative pharmacology specialist), the company enhanced its pharmacometric capabilities. Key service packages include DMPK Strategy, Toxicology Study, Clinical Efficacious Dose, Target Product Profile, and Out-Licensing Support, supported by specialized expert teams organized by function (Clinical Pharmacology, Non-clinical, Regulatory Strategy, Pharmacometrics, etc.). The company has served over 170 clients across 320+ projects.
Differentiator
Problem solved
Functional benefit
Products and services
- Strategy Consulting Consulting service providing strategic planning for drug development including Target Product Profile definition, nonclinical and clinical development strategy, study design, and regulatory strategy for biotech and pharma clients.
- Study Outsourcing Service managing the outsourcing of drug development studies including DMPK/Tox, efficacy/potency studies, and clinical research through a network of trusted CRO partners such as Selvita/Fidelta, DT&CRO, WuXi AppTec, Pharmaron, Lovelace Biomedical, EVOTEC, Charles River, and Biomodels.
- Modeling & Simulation (M&S) / Pharmacometrics Pharmacometric analysis service that determines pharmacokinetic characteristics using mathematical models (PBPK, PK-PD, NCA) to describe drug exposure-response, support dose optimization, clinical trial design, and regulatory submissions.
- Technology Commercialization Service supporting government fund applications, asset valuation, IP consulting, and investment for technology commercialization, delivered in partnership with Budia.
- IND Enabling Services Services including gap analysis, nonclinical development strategy, and IND-enabling study management to support Phase 1 clinical trial initiation for biotech and pharma clients.
- DMPK Services Drug metabolism and pharmacokinetics consulting covering bioanalysis, in vitro ADME, in vivo PK, drug-drug interaction studies, and PK/PD study design.
- CMC Consulting Chemistry, Manufacturing and Controls consulting including preformulation, formulation, drug substance (DS), and drug product (DP) development support.
- Clinical Development Services Services covering early and late phase clinical studies, clinical pharmacology studies (first-in-human, SAD/MAD, food effect, special populations), clinical study management, and regulatory submission support.
- Toxicology Consulting Consulting for in vitro toxicology, safety pharmacology, general toxicology, and other specialized toxicology studies.
- Pharmacology Services In vitro and in vivo pharmacology consulting including assay design, animal model selection, and CRO management.
- EuroscreenFast Distribution Official Korean distribution of EuroscreenFast GPCR functional assays and screening services, offering more than 1,000 diverse functional assays including over 530 GPCRs, ion channels, kinases, and various enzymes to Korean biotech and pharma clients.
Companies that use AIMS BioScience
Customer profileNamed customers13 records
Segments2 records
Ideal customer profiles2 records
AIMS BioScience technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
AIMS BioScience partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered major, core and minor.
- BioMarketingLabmajorStrategic partnership for drug commercialization and marketing support.
- Korean Innovation Drug ConsortiummajorMOU signed for collaborative drug development and innovation initiatives.
- OPIS (Italy)majorGlobal clinical MOU signed with OPIS, an Italian CRO, for international clinical development collaboration.
- Q-fitter (큐피터)coreAIMS BioScience merged with Q-fitter on April 1, 2023, making AIMS the sole provider of quantitative pharmacology services in Korea. Q-fitter was the only company in Korea providing quantitative pharmacology services. The merger was commemorated with a seminar at Gravity Seoul Pangyo featuring approximately 200 industry and academic participants.
- ImmunePalzminorMOU for autoimmune C5 antibody clinical development collaboration.
- NeoNanaminorRNA-based anticancer drug IND agreement for collaborative development.
- MolrimminorJoint research MOU for new drug development collaboration.
- Q-fitter (prior to merger)coreInitial joint research MOU before the 2023 merger, establishing the partnership that led to full integration.
- Seoul National UniversitycoreJoint research MOU for new drug development with Seoul National University.
- EuroscreenFastcoreAIMS BioScience is the official distributor in Korea for EuroscreenFast, a pioneer in GPCR science with over 30 years of expertise. EuroscreenFast offers more than 1,000 diverse functional assays including over 530 GPCRs, ion channels, kinases, and various enzymes.
- Selvita/Fidelta, DT&CRO, WuXi AppTec, Pharmaron, Lovelace Biomedical, EVOTEC, Charles River, BiomodelscoreTrusted nonclinical product quality partners including DMPK/Toxicology CROs for preclinical study outsourcing.
- Parexel, Covance, C&R Research, The Catholic University Seoul St. Mary's Hospital, Eurofins ScientificcoreClinical partners for conducting clinical trials and CRO recruitment/management.
- PIPET (Seoul National University Bundang Hospital), iCBigD3coreTranslational research partners for pharmacometrics education, training, and analysis.
Scale indicators2 records
Recent moves7 records
Expansion highlights4 records
AIMS BioScience competitors and assessment
Company assessmentDirect peers
- DreamCIS: South Korean CRO offering clinical research, statistical analysis, and regulatory services to biopharma. Direct Korean peer competing with AIMS for the same domestic biotech and pharma clients.
- Metrum Research Group: US-based pharmacometrics and clinical pharmacology consulting firm providing PK/PD modeling, simulation, and quantitative analysis for drug development. Operates in the same niche as AIMS BioScience's modeling & simulation service line.
- Pharmetheus: Sweden-based pharmacometrics consulting firm offering population PK/PD modeling, PBPK, and clinical pharmacology services. Direct competitor in the quantitative pharmacology consulting segment that AIMS BioScience addresses in Korea.
- Certara: Global leader in model-informed drug development, biosimulation, and regulatory science consulting. Directly comparable to AIMS in pharmacometrics (PK/PD, PBPK modeling), clinical pharmacology consulting, and regulatory strategy services for biopharma clients.
- Simulations Plus: Provides modeling and simulation software plus services (formerly including Cognigen) for pharmacokinetics, pharmacodynamics, and quantitative pharmacology. Overlaps with AIMS' modeling & simulation and PBPK/PK-PD service offerings.
- C&R Research: Korean CRO listed as an AIMS partner for clinical trials. Comparable Korean clinical research services peer serving the same domestic pharmaceutical and biotech client base.
- LSK Global PS Services: South Korean contract research organization providing clinical trial management, biostatistics, and pharmacovigilance services. Comparable as a domestic Korean CRO competitor to AIMS BioScience in the local drug development services market.
Broad incumbents
- Parexel International: Global CRO offering clinical development, regulatory, and consulting services across the full drug development lifecycle. AIMS lists Parexel as a clinical partner but Parexel also competes broadly in the consulting and study outsourcing space AIMS occupies.
- IQVIA: World's largest CRO with extensive pharmacometrics, clinical pharmacology, and regulatory consulting capabilities. A broad incumbent whose expansion into Asian pharmacometrics could challenge AIMS' niche positioning over time.
- Charles River Laboratories: Global nonclinical CRO providing DMPK, toxicology, and safety pharmacology services. Listed as a nonclinical partner of AIMS, but also a broad incumbent that could integrate vertically to bypass boutique consulting coordinators.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
AIMS BioScience social profiles
Digital presenceAIMS BioScience financial estimates
Financial estimateRevenue estimate
Valuation estimate
AIMS BioScience leadership team
Management profileNumber of profiles
Profiles2 records
AIMS BioScience subsidiaries and ownership
Company hierarchySubsidiaries1 record
AIMS BioScience funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AIMS BioScience M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AIMS BioScience
What does AIMS BioScience do?
AIMS BioScience is a Korea-based B2B drug development consulting firm that delivers strategy consulting, study outsourcing, and pharmacometric modeling & simulation services to biotech and pharmaceutical companies. The firm supports clients across preclinical, clinical pharmacology, CMC, regulatory strategy, and licensing-out stages, and is also the official Korean distributor of EuroscreenFast GPCR functional assays.
Is AIMS BioScience a public or private company?
AIMS BioScience is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was AIMS BioScience founded?
AIMS BioScience was founded in -1. It employs 11 to 50 people.
Where is AIMS BioScience based?
AIMS BioScience is headquartered in Seoul, South Korea, in the Asia region.
How does AIMS BioScience make money?
Three revenue lines are on record. Strategy Consulting is the primary driver. The others are study Outsourcing and euroscreenFast Distribution.
Who are AIMS BioScience's main competitors?
Direct peers on record are DreamCIS, Metrum Research Group, Pharmetheus, Certara, Simulations Plus, C&R Research and LSK Global PS Services. Broad incumbents are Parexel International, IQVIA and Charles River Laboratories.
Does AIMS BioScience have an API?
No public API is recorded for AIMS BioScience.
What industry is AIMS BioScience in?
AIMS BioScience's product category is Drug Development Consulting Services. Its primary akta.pro industry code is HLAGALAF, Medical Affairs Scientific Communications (MSL Support/Scientific Response), with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 5417 and its SIC code is 8731.